Evaluation of Antidiabetic Activity of the Polyherbal Formulation (PF-4) in the Management of Madhumeha (Diabetes Mellitus)


  • Susmita Chakraborty Medical Officer, WBH & FW, Kaliyaganj, India


polyherbal formulation, madhumeha


The antidiabetic activity of (PF-4) was evaluated by different scientific parameters after performing the pharmacognostic study, phytochemical study, toxicological study, experimental study on alloxan induced diabetic model. Dose selection was made on the basis of acute oral toxicity study as per OECD guidelines. In acute toxicity test, there was no such toxicity or no mortality found up to the dose of 1000 mg/kg body weight. In (OGTT) test at 30 min after oral glucose administration, the blood glucose level increased rapidly from the fasting value in all groups, and then subsequently decreased at 60 min and 90 min. In 60 min, (PF-4)-700mg /kg body weight and (PF-4)-500 mg/kg body weight both exhibited remarkable blood glucose lowering effect which was very close to the standard drug (Glibenclamide) and both groups (PF-4)700mg/k.g b.w and (PF-4)500 mg /k.g b.w) significantly(p<0.001)lowered blood glucose level. In 90 min, (PF-4) also exhibited significant inhibition of blood glucose but (PF-4) 700 mg /kg b.w highly significant(p<0.01) than (PF-4)500 mg/k.g b.w(p<0.05). So the maximum hypoglycaemic effect of (PF-4) has been observed at 60 min, comparing with control and standard group. In alloxan induced diabetic model, both doses of (700 mg/kg body weight and 500 mg/kg body weight of PF-4 significantly (P<0.001) decreased the blood glucose in comparison with control group. The drug has the potential to act as an antidiabetic drug.




How to Cite

S. Chakraborty, “Evaluation of Antidiabetic Activity of the Polyherbal Formulation (PF-4) in the Management of Madhumeha (Diabetes Mellitus)”, IJRAMT, vol. 3, no. 5, pp. 8–11, May 2022.